|
EP2724723A1
|
|
Tegaserod for use in the treatment of nerve injuries
|
|
EP2669679A1
|
|
Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
|
|
WO2012098226A2
|
|
Visualization of lipid metabolism
|
|
EP2609914A1
|
|
Novel methods for treating or preventing neurodegeneration
|
|
DE102011122025A1
|
|
Device and system for determining brain activity
|
|
DE102011121317A1
|
|
Scaffold-free liver cell aggregates for use in transplantation
|
|
DE102011121237A1
|
|
Single domain antibody to Clostridium difficile toxin CDTa
|
|
DE102011121238A1
|
|
SINGLE DOMAIN ANTIBODY AGAINST CLOSTRIDIUM DIFFICILE TOXINE
|
|
EP2591801A1
|
|
Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions
|
|
EP2548567A1
|
|
Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
|
|
EP2535717A1
|
|
Method for determining the mortality risk
|
|
EP2505661A1
|
|
Methods for detecting the mortality risk
|
|
DE102010060964A1
|
|
Method for predicting the therapeutic efficacy of EGFR inhibitors
|
|
DE102010045798A1
|
|
The blood collection device
|
|
EP2385068A1
|
|
Polyclonal antiserum for use in immunotherapy
|
|
EP2380991A1
|
|
Method of determining the metastatic potential of a tumor
|
|
EP2384752A1
|
|
Combination preparation comprising a phosphodiesterase inhibitor and a COX inhibitor for treating cancer
|
|
EP2366431A1
|
|
Myeloperoxidase as a target in atrial fibrillation
|
|
EP2363501A1
|
|
Method for isolating target cells
|
|
EP2327412A1
|
|
Treatment of nerve injuries
|
